GTS Securities’s Direxion Daily Biotech Top 5 Bull 2X ETF TBXU Stock Holding History

GTS Securities’s Portfolio TBXU Stock Details TBXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$479K	Sell	15,274 -8,036	-34%	-$265K	0.02%	767
2025 Q4	$724K	Buy	+23,310	New	+$696K	0.02%	588

Other funds holding TBXU

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GTS Securities's TBXU Position: Q1 2026 in Review

GTS Securities reduced its Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) stake by 34% in Q1 2026, selling an estimated $265K and leaving 15,274 shares worth $479K. The position accounts for 0.02% of the portfolio, ranked #767.

GTS Securities first reported a position in TBXU in Q4 2025 and has held it in 2 quarters since. The position peaked at $724K in Q4 2025. 3 funds tracked by Wall St. Rank hold TBXU as of Q1 2026.

GTS Securities held 15,274 shares of Direxion Daily Biotech Top 5 Bull 2X ETF worth $479K as of Q1 2026.
GTS Securities sold 8,036 Direxion Daily Biotech Top 5 Bull 2X ETF shares in Q1 2026, an estimated $265K.
Direxion Daily Biotech Top 5 Bull 2X ETF made up 0.02% of GTS Securities's portfolio in Q1 2026, its #767 holding.
GTS Securities first reported a position in Direxion Daily Biotech Top 5 Bull 2X ETF in Q4 2025 and has held it in 2 quarters since.
GTS Securities's Direxion Daily Biotech Top 5 Bull 2X ETF position peaked at $724K in Q4 2025.
3 funds tracked by Wall St. Rank held Direxion Daily Biotech Top 5 Bull 2X ETF as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.